Biopharma financings totaled $21.38 billion through May 2025, down sharply from $62.57 billion during the same period in 2024 ...

Researchers from the University of Arizona have unveiled that coordinated Y chromosome loss in both cancer cells and immune ...

Turning the human body into a biofactory of precision protein therapeutics is the focus of newly launched Signify Bio, which ...

Aiatella Oy secured €2 million (US$2.28 million) in funding for its AI-powered cardiovascular imaging technology. The funds ...

The BioWorld Biopharmaceutical Index extended its downward trend over April and May, closing the latter month down 6.47% after reaching a peak gain of 9.64% at the end of February. The Nasdaq ...

As it advances its nonopioid analgesic ATX-101 breakthrough therapy through a phase IIb registration trial, Allay Therapeutics secured $57.5 million in a series D round, which included an investment ...

A publication based on longitudinal and cross sectional data and led by researchers at the U.S. NIH’s National Institute on ...

Researchers at ETH Zürich developed Menstruai, a device that detects in menstruation blood biomarkers associated with certain ...

The U.S. FDA posted notice of six class I device recalls between June 3 and June 5, 2025, four of which are for corrections.

Astrazeneca AB has divulged 17β-hydroxysteroid dehydrogenase 13 (HSD17B13; 17β-HSD13) inhibitors reported to be useful for the treatment of alcoholic liver disease, liver fibrosis, cirrhosis, hepatic ...

The EMA’s Committee for Orphan Medicinal Products (COMP) has issued a positive opinion recommending European orphan drug designation for Hemispherian AS’s GLIX-1 for the treatment of glioma.

Solvonis Therapeutics plc has completed synthesis of development candidates for its SVN-SDN-014 program, a novel series of serotonin, dopamine and noradrenaline modulators.